Tweet
New SARM Causing Controversy, Is It An Anabolic Steroid Or Not?
Full Name: (17-alpha,20E) 17,20-
[(1-methoxyethylidene)bis(oxy)]
3-oxo-19-norpregna-4,20-diene 21-carboxylic acid methyl ester
In 2011, Yuichiro Kanno of Toho University published the results of an initial study on YK11, confirming that the rare compound was a SARM.
YK11 attaches itself to the AR (androgen receptor), but only inducts methods that lead to the traditional side effects of androgens such as growth of body hair and prostate and enhanced aggression – to a restricted degree.
Most SARMS have quite limited androgenic side effects, but frequently only quite few anabolic effects when likened to testosterone. But, this doesn’t occur for YK11 as reported in Biological and Pharmaceutical Bulletin in 2013.
Kanno tested C2C12 muscle cells and not lab animals or humans. It has been discovered that muscle cells produce more anabolic factors if exposed to 500 nmol (nanomoles) YK11 than if you expose the same muscle cells to 500 nmol DHT.
YK11 induces muscle cells to make more follistatin (more than DHT does) – a strong myostatin inhibitor. YK11 works through the androgen receptor.
With that said, YK11 can be as good as testosterone in terms of muscle strengthening, but minus the detrimental side effects.
Conclusion
YK11 shows a lot of promise as an apt anabolic SARM. With the muscle growth potential it brings, it’s as effective as anabolic steroids and prohormones without the unwanted side effects connected to the latter.
____________________
NOT SO FAST.. IT'S NOT A SARM AFTER ALL
The current information on the internet about YK-11, is some what incorrect and by no means complete. YK-11 is not a SARM. It's a testosterone (Test)/ 5-α-dihydrotestosterone (DHT) derivative a synthetic anabolic steroid. YK-11 possess the same steroid backbone as all other chemicals classified as steroid hormones.
Given that we now know that YK-11 is a designer anabolic steroid it likely possess the typical side effects associated anabolic steroid which we can now assigned to YK-11. YK-11 has 4 methyl (CH3) groups and so will likely prove taxing to the liver; SARMs have reduced liver toxicity profile because they have substituted methyl groups with Halocarbons. In addition, data produced by Kanno Y et al 2013 demonstrate that YK-11 induces the production of follistatin, a glycoprotein that inhibits myostatin a protein which inhibits myogenesis (the development/formation of new muscle tissue/fibers during embryonic development and also extant in adult muscle tissue). Follistatin is also associated with prostate growth and so being targeted as such (Follistatin as potential therapeutic target in prostate cancer.)
YK-11 is derivative of the anabolic steroid DHT, and as partial agonist of the androgen receptor it would activate the androgen receptor to give a submaximal response when inadequate amounts of DHT or Test are present. In the presence of overstimulation of androgen receptors say when excess amounts of DHT or Test are present YK-11 will act as a competitive inhibitor of androgen receptors . This is because partial agonists typically display both agonistic and antagonistic properties.
To conclude, YK-11 is a synthetic steroid with anabolic and likely undiscovered progestin potential. Because YK-11 is partial agonist to the androgen receptor it will be in direct competition with Test and DHT for binding and so its anabolic activity may be reliant on its ability to stimulate follistatin. Because of its partial agonist competition with Test and DHT it may reduce anabolic activity in otherwise healthy males. To date no safety data or animal testing exist.
Full Name: (17-alpha,20E) 17,20-
[(1-methoxyethylidene)bis(oxy)]
3-oxo-19-norpregna-4,20-diene 21-carboxylic acid methyl ester
In 2011, Yuichiro Kanno of Toho University published the results of an initial study on YK11, confirming that the rare compound was a SARM.
YK11 attaches itself to the AR (androgen receptor), but only inducts methods that lead to the traditional side effects of androgens such as growth of body hair and prostate and enhanced aggression – to a restricted degree.
Most SARMS have quite limited androgenic side effects, but frequently only quite few anabolic effects when likened to testosterone. But, this doesn’t occur for YK11 as reported in Biological and Pharmaceutical Bulletin in 2013.
Kanno tested C2C12 muscle cells and not lab animals or humans. It has been discovered that muscle cells produce more anabolic factors if exposed to 500 nmol (nanomoles) YK11 than if you expose the same muscle cells to 500 nmol DHT.
YK11 induces muscle cells to make more follistatin (more than DHT does) – a strong myostatin inhibitor. YK11 works through the androgen receptor.
With that said, YK11 can be as good as testosterone in terms of muscle strengthening, but minus the detrimental side effects.
Conclusion
YK11 shows a lot of promise as an apt anabolic SARM. With the muscle growth potential it brings, it’s as effective as anabolic steroids and prohormones without the unwanted side effects connected to the latter.
____________________
NOT SO FAST.. IT'S NOT A SARM AFTER ALL
The current information on the internet about YK-11, is some what incorrect and by no means complete. YK-11 is not a SARM. It's a testosterone (Test)/ 5-α-dihydrotestosterone (DHT) derivative a synthetic anabolic steroid. YK-11 possess the same steroid backbone as all other chemicals classified as steroid hormones.
Given that we now know that YK-11 is a designer anabolic steroid it likely possess the typical side effects associated anabolic steroid which we can now assigned to YK-11. YK-11 has 4 methyl (CH3) groups and so will likely prove taxing to the liver; SARMs have reduced liver toxicity profile because they have substituted methyl groups with Halocarbons. In addition, data produced by Kanno Y et al 2013 demonstrate that YK-11 induces the production of follistatin, a glycoprotein that inhibits myostatin a protein which inhibits myogenesis (the development/formation of new muscle tissue/fibers during embryonic development and also extant in adult muscle tissue). Follistatin is also associated with prostate growth and so being targeted as such (Follistatin as potential therapeutic target in prostate cancer.)
YK-11 is derivative of the anabolic steroid DHT, and as partial agonist of the androgen receptor it would activate the androgen receptor to give a submaximal response when inadequate amounts of DHT or Test are present. In the presence of overstimulation of androgen receptors say when excess amounts of DHT or Test are present YK-11 will act as a competitive inhibitor of androgen receptors . This is because partial agonists typically display both agonistic and antagonistic properties.
To conclude, YK-11 is a synthetic steroid with anabolic and likely undiscovered progestin potential. Because YK-11 is partial agonist to the androgen receptor it will be in direct competition with Test and DHT for binding and so its anabolic activity may be reliant on its ability to stimulate follistatin. Because of its partial agonist competition with Test and DHT it may reduce anabolic activity in otherwise healthy males. To date no safety data or animal testing exist.
Comment